Stocks · News reference

8-K filing — Ovid Therapeutics Inc. (OVID)

Jul 8, 2026, 11:03 AMSEC EDGAR

Filed: 2026-07-08 AccNo: 0001628280-26-047584 Size: 149 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

OVID

Source: edgar
Observed: Jul 8, 2026, 11:03 AM
Checked: Jul 8, 2026, 11:03 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 13, 2026, 12:58 PMBenzinga Newsdesk
Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.06) per share
Read original at benzinga
OVID
BenzingaAug 3, 2026, 2:25 PMBenzinga Newsdesk
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9
Oppenheimer analyst Kostas Biliouris maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and raises the price target from $7 to $9.
Read original at benzinga
OVID
BenzingaJul 8, 2026, 11:28 AMBenzinga Newsdesk
Ovid Therapeutics Promotes Charles Carter As CFO Succeeding Jeffrey Rona
Read original at benzinga
OVID

8-K filing — Ovid Therapeutics Inc. (OVID)

Connected markets

Related headlines

Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K Estimate

Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9

Ovid Therapeutics Promotes Charles Carter As CFO Succeeding Jeffrey Rona